The PAAG regimen significantly improved PFS and response rates in metastatic pancreatic cancer compared to chemotherapy alone ...

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Please provide your email address to receive an email when new articles are posted on . Results showed longer median PFS and a higher 9-month PFS with ivonescimab than pembrolizumab. Patients with ...

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall ...

But is the combination a "viable alternative" to nivolumab and ipilimumab?